Etanercept
- Generic Name
- Etanercept
- Brand Names
- Enbrel, Eticovo, Benepali, Erelzi, Nepexto
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 185243-69-0
- Unique Ingredient Identifier
- OP401G7OJC
- Background
Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids. It is used to treat or manage a variety of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and juvenile idiopathic poly-articular arthritis (JIA).
- Indication
Etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and in chronic moderate to severe plaque psoriasis in patients 4 years of age and older. It is also used to manage signs and symptoms of polyarticular idiopathic arthritis and Juvenile Psoriatic Arthritis in those aged 2 years and older. Etanercept is also used to manage the symptoms of psoriatic arthritis and ankylosing spondylitis.
- Associated Conditions
- Active Juvenile Psoriatic Arthritis, Ankylosing Spondylitis (AS), Graft-versus-host Disease (GVHD), Polyarticular Juvenile Idiopathic Arthritis, Psoriasis Vulgaris (Plaque Psoriasis), Psoriatic Arthritis, Pyoderma Gangrenosum, Rheumatoid Arthritis, Severe Plaque psoriasis, Stevens-Johnson Syndrome, Chronic, severe Psoriatic Arthritis, Moderate Plaque psoriasis, Moderate, active Rheumatoid arthritis, Severe, active Rheumatoid arthritis
- Associated Therapies
- -
Etanercept (Enbrel) in Ankylosing Spondylitis
- First Posted Date
- 2011-02-04
- Last Posted Date
- 2011-02-04
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 24
- Registration Number
- NCT01289743
- Locations
- 🇩🇪
Charite Campus Benjamin Franklin, Rheumatology, Berlin, Germany
🇩🇪Rheumazentrum Ruhrgebiet, Herne, Germany
Withdrawal of Etanercept After Successful Treatment of Juvenile Idiopathic Arthritis
- First Posted Date
- 2011-02-01
- Last Posted Date
- 2011-02-01
- Lead Sponsor
- Erasmus Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT01287715
- Locations
- 🇳🇱
Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands
🇳🇱Utrecht Medical Centre Wilhelmina Children's Hospital, Utrecht, Netherlands
🇳🇱Sint-Lucas Andreas Hospital, Amsterdam, Netherlands
A Study to Assess the Effect of Ustekinumab (Stelara®) and Etanercept (Enbrel®) in Participants With Moderate to Severe Psoriasis (MK-0000-206)
- First Posted Date
- 2011-01-13
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 40
- Registration Number
- NCT01276847
Psoriasis Inflammation and Systemic Co Morbidities
- First Posted Date
- 2010-07-27
- Last Posted Date
- 2021-02-08
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 29
- Registration Number
- NCT01170715
- Locations
- 🇺🇸
The Rockefeller University, New York, New York, United States
Study Evaluating the Safety and Effectiveness of Etanercept for the Treatment of Pediatric Psoriasis
- First Posted Date
- 2010-04-08
- Last Posted Date
- 2019-10-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 72
- Registration Number
- NCT01100034
- Locations
- 🇭🇺
Heim Pal Children's Hospital, Budapest, Hungary
🇬🇷Skin and Venereal Diseases' Hospital, Thessaloniki, Greece
🇬🇷University of Athens, Andreas Syngros Hospital, Athens, Greece
Can We Miss Pigmented Lesions in Psoriasis Patients?
- First Posted Date
- 2010-01-21
- Last Posted Date
- 2018-02-23
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 6
- Registration Number
- NCT01053819
- Locations
- 🇺🇸
UAB Dermatology, Birmingham, Alabama, United States
Etanercept for the Treatment of Chronic Urticaria
- First Posted Date
- 2009-12-11
- Last Posted Date
- 2015-06-02
- Lead Sponsor
- University of Utah
- Registration Number
- NCT01030120
- Locations
- 🇺🇸
University of Utah Department of Dermatology, Salt Lake City, Utah, United States
Human Tumor Necrosis Factor Alpha (TNFa)-Induced Pre-B Cell Bone Marrow Emigrants
- First Posted Date
- 2009-11-09
- Last Posted Date
- 2013-07-02
- Lead Sponsor
- University of Pittsburgh
- Registration Number
- NCT01009879
- Locations
- 🇺🇸
University of Pittsburgh - Oakland Falk Clinic, Pittsburgh, Pennsylvania, United States
The Efficacy and Safety of Adding Methotrexate to Etanercept in Psoriasis
- First Posted Date
- 2009-10-26
- Last Posted Date
- 2013-08-12
- Lead Sponsor
- Amgen
- Target Recruit Count
- 478
- Registration Number
- NCT01001208
Study Comparing 2 Different Strategies For Management of Subjects With Plaque Psoriasis Who Have Responded to Etanercept
- First Posted Date
- 2009-10-09
- Last Posted Date
- 2016-01-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 174
- Registration Number
- NCT00992394
- Locations
- 🇭🇺
Miskolci Egeszsegugyi Kozpont, Miskolc, Hungary
🇩🇪J. W. Goethe Universitaet Frankfurt, Zentrum fuer Dermatologie und Venerologie, Frankfurt am Main, Germany
🇫🇷CHU de l Archet, Nice Cedex 03, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.